Acute pharmacological modulation of mGluR8 reduces measures of anxiety

Behavioural Brain Research

Volumn 212, Issue 2, 2010, Pages 168-173

  Duvoisin, Robert M ^a   Pfankuch, Tim ^b   Wilson, Julie M ^c   Grabell, Julie ^c   Chhajlani, Vijay ^d   Brown, Dean G ^d   Johnson, Edwin ^d   Raber, Jacob ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NPS Pharmaceuticals Inc   (Canada)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Allosteric modulator; Behavior; Group III mGluR; Metabotropic

Indexed keywords

3,4 DICARBOXYPHENYLGLYCINE; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; AZ 12216052; GLUTAMIC ACID; METABOTROPIC RECEPTOR 8; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG; 3,4-DICARBOXYPHENYLGLYCINE; ACETANILIDE DERIVATIVE; BENZOIC ACID DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; GLYCINE; METABOTROPIC RECEPTOR; THIOGLYCOLIC ACID DERIVATIVE;

ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME DEGRADATION; GABAERGIC TRANSMISSION; HUMAN; HUMAN CELL; MALE; MAZE TEST; MOUSE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; STARTLE REFLEX; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANXIETY; C57BL MOUSE; DRUG EFFECTS; DRUG THERAPY; GENETICS; HEARING; KNOCKOUT MOUSE; METABOLISM; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; TIME;

ACETANILIDES; ANIMALS; ANXIETY; APOLIPOPROTEINS E; AUDITORY PERCEPTION; BENZOATES; CENTRAL NERVOUS SYSTEM AGENTS; GLYCINE; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION; THIOGLYCOLATES; TIME FACTORS; REFLEX, STARTLE;

EID: 77953020355     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.04.006     Document Type: Article

References (47)

1. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34:1-26.
2. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
3. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000, 75:889-907.
4. Duvoisin R.M., Zhang C., Ramonell K. A novel metabotropic glutamate receptor expressed in the retina and olfactory bulb. J Neurosci 1995, 15:3075-3083.
5. Saugstad J.A., Kinzie J.M., Shinohara M.M., Segerson T.P., Westbrook G.L. Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct pharmacological profile. Mol Pharmacol 1997, 51:119-125.
6. Swanson C., Bures M., Johnson M., Linden A.-M., Monn J., Schoepp D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Disc 2005, 4:131-144.
7. Linden A.M., Johnson B.G., Peters S.C., Shannon H.E., Tian M., Wang Y., et al. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 2002, 43:251-259.
8. Duvoisin R., Zhang C., Pfankuch T., O'Connor H., Gayet-Primo J., Quraishi S., et al. Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8. Eur J Neurosci 2005, 22:425-436.
9. Fendt M., Bürki H., Imobersteg S., van der Putten H., McAllister K., Leslie J.C., et al. The effect of mGlu(8) deficiency in animal models of psychiatric diseases. Genes Brain Behav 2009, 9:33-44.
10. Duvoisin R.M., Villasana L., Pfankuch T., Raber J. Sex-dependent cognitive phenotype of mice lacking mGluR8. Behav Brain Res 2010, 209:21-26.
11. Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 1986, 88:147-152.
12. Swerdlow N.R., Britton K.T., Koob G.F. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by α-helical CRF (9-14). Neuropsychopharmacology 1989, 2:285-292.
13. Liang K.C., Melia K.R., Miserendino M.J.D., Falls W.A., Campeau S., Davis M. Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 1992, 12:2303-2312.
14. Bastos L.C., Tonussi C.R. PGE2-induced lasting nociception to heat: evidence for a selective involvement of A-delta fibres in the hyperpathic component of hyperalgesia. Eur J Pain 2010, 14:113-119.
15. Thomas N.K., Wright R.A., Howson P.A., Kingston A.E., Schoepp D.D., Jane D.E. (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 2001, 40:311-318.
16. Benice T., Rizk A., Pfankuch T., Kohama S., Raber J. Sex-differences in age-related cognitive decline in C57BL/6J mice associated with increased brain microtubule-associated protein 2 and synaptophysin immunoreactivity. Neuroscience 2006, 137:413-423.
17. Robertson J., Curley J., Kaye J., Quinn J., Pfankuch T., Raber J. apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice. Neurobiol Aging 2005, 26:637-643.
18. -/- mice: possible role in behavioral and metabolic alterations. J Neurosci 2000, 20:2064-2071.
19. Bongers G., Leurs R., Robertson J., Raber J. Role of H3 receptor-mediated signaling in anxiety and cognition in wild-type and Apoe-/- mice. Neuropsychopharmacology 2004, 29:441-449.
20. Helton D., Tizzano J., Monn J., Schoepp D., Kallman M. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998, 284:651-660.
21. Klodzinska A., Bijak M., Tokarski K., Pilc A. Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 2002, 73:327-332.
22. Tizzano J., Griffey K., Schoepp D. The anxiolytic action of mGlu2/3 receptor agonist LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 2002, 73:367-374.
23. Linden A.M., Baez M., Bergeron M., Schoepp D.D. Increased c-Fos expression in the centromedial nucleus of the thalamus in metabotropic glutamate 8 receptor knockout mice following the elevated plus maze test. Neuroscience 2003, 121:167-178.
24. Linden A.M., Bergeron M., Baez M., Schoepp D.D. Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-Fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice. Neuropharmacology 2003, 45:473-483.
25. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997, 40:528-537.
26. Grillon C., Cordova J., Levine L.R., Morgan C.A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003, 168:446-454.
27. Stachowicz K., Kłak K., Pilc A., Chojnacka-Wójcik E. Lack of the antianxiety-like effect of (S)-3,4-DCPG, an mGlu8 receptor agonist, after central administration in rats. Pharmacol Rep 2005, 57:856-860.
28. Schmid S., Fendt M. Effects of the mGluR8 agonist (S)-3,4-DCPG in the lateral amygdala on acquisition/expression of fear-potentiated startle, synaptic transmission, and plasticity. Neuropharmacology 2006, 50:154-164.
29. Palazzo E., Fu Y., Ji G., Maione S., Neugebauer V. Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors. Neuropharmacology 2008, 55:537-545.
30. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2002, 9:76-81.
31. Rahn E.J., Zvonok A.M., Thakur G.A., Khanolkar A.D., Makriyanic A., Hohman A.G. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 2008, 327:584-591.
32. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93:239-245.
33. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., et al. CB2 cannaboid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005, 102:3093-3098.
34. Fossum E.N., Lisowski M.J., Macey T.A., Ingram S.L., Morgan M.M. Microinjection of the vehicle dimethyl sulfoxide (DMSO) into the periaquaductal gray modulates morphine nociception. Brain Res 2008, 1204:53-58.
35. Morgan C.A., Southwick S.M., Grillon C., Davis M., Krystal J.H., Charney D.S. Yohimbine-facilitated acoustic startle reflex in humans. Psychopharmacology 1992, 110:342-346.
36. Killcross S., Robbins T.W., Everitt B.J. Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Nature 1997, 388:377-380.
37. Haas H. Histamine potentiates neuronal excitation by blocking a calcium-dependent potassium conductance. Agents Actions 1984, 14:534-537.
38. Bekkers Enhancement by histamine of NMDA-mediated synaptic transmission in the hippocampus. Science 1993, 261:104-106.
39. Vorobjev V., Sharanova I., Walsh I., Haas H.L. Histamine potentiates N-methyl-d-apartate responses in acutely isolated hippocampal neurons. Neuron 1993, 11:837-844.
40. Brown R., Fedorov N., Haas H.L., Reymann K.G. Histaminergic modulation of synaptic plasticity in area CA1 of rat hippocampal slices. Neuropharmacology 1995, 34:181-190.
41. Brown R., Reymann K.G. Histamine H3 receptor-mediated depression of synaptic transmission in the dentate gyrus of the rat in vitro. J Physiol Lond 1996, 496:175-184.
42. Payne G., Neumann R. Effect of hypomagnesia on histamine H1 receptor-mediated facilitation of NMDA responses. Br J Pharmacol 1997, 121:199-204.
43. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Prog Neurobiol 2001, 63:637-672.
44. Schlegel S., Steinert H., Bockisch A., Hahn K., Schloesser R., Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci 1994, 244:49-51.
45. Kaschka W., Feistel H., Ebert D. Reduced benzodiazepine receptor binding in panic disorder measured by IOMAZENIL SPECT. J Psychiatr Res 1995, 29:427-434.
46. Roy-Byrne P., Wingerson D., Radant A., Greenblatt D., Cowley D. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am J Psychiatr 1996, 153:1444-1449.
47. Sundstrom I., Ashbrook D., Backstrom T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997, 22:25-38.